# The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

> **NCT05317767** · PHASE3 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 600 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flu-M [Inactivated split influenza vaccine]
- **BIOLOGICAL:** Inactivated Split Influenza Vaccine

## Key facts

- **NCT ID:** NCT05317767
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2020-07-05
- **Final completion:** 2020-09-14
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05317767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05317767, "The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05317767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*